NovoCure Past Earnings Performance
Past criteria checks 0/6
NovoCure's earnings have been declining at an average annual rate of -57.4%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 6.9% per year.
Key information
-57.4%
Earnings growth rate
-56.7%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 6.9% |
| Return on equity | -41.5% |
| Net Margin | -25.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01
Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Oct 17NovoCure: There Is Still More Upside
Oct 16NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Oct 09Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
Sep 12NovoCure Limited: A Post Q2 Analysis
Jul 26NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16Revenue & Expenses Breakdown
How NovoCure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 578 | -150 | 382 | 210 |
| 30 Jun 24 | 550 | -169 | 382 | 212 |
| 31 Mar 24 | 526 | -193 | 387 | 213 |
| 31 Dec 23 | 509 | -207 | 387 | 221 |
| 30 Sep 23 | 504 | -197 | 380 | 224 |
| 30 Jun 23 | 508 | -174 | 354 | 222 |
| 31 Mar 23 | 522 | -141 | 331 | 224 |
| 31 Dec 22 | 538 | -93 | 306 | 206 |
| 30 Sep 22 | 543 | -82 | 289 | 208 |
| 30 Jun 22 | 545 | -68 | 279 | 204 |
| 31 Mar 22 | 538 | -59 | 269 | 198 |
| 31 Dec 21 | 535 | -58 | 263 | 201 |
| 30 Sep 21 | 546 | -27 | 253 | 188 |
| 30 Jun 21 | 545 | -5 | 246 | 173 |
| 31 Mar 21 | 527 | 12 | 232 | 153 |
| 31 Dec 20 | 494 | 20 | 225 | 132 |
| 30 Sep 20 | 450 | 19 | 216 | 112 |
| 30 Jun 20 | 409 | 12 | 206 | 98 |
| 31 Mar 20 | 380 | 9 | 197 | 87 |
| 31 Dec 19 | 351 | -7 | 185 | 79 |
| 30 Sep 19 | 322 | -27 | 174 | 70 |
| 30 Jun 19 | 294 | -41 | 166 | 65 |
| 31 Mar 19 | 269 | -55 | 158 | 57 |
| 31 Dec 18 | 248 | -64 | 151 | 51 |
| 30 Sep 18 | 232 | -59 | 143 | 46 |
| 30 Jun 18 | 217 | -59 | 137 | 42 |
| 31 Mar 18 | 194 | -64 | 131 | 40 |
| 31 Dec 17 | 177 | -62 | 123 | 38 |
| 30 Sep 17 | 154 | -73 | 115 | 37 |
| 30 Jun 17 | 125 | -95 | 112 | 37 |
| 31 Mar 17 | 105 | -114 | 108 | 39 |
| 31 Dec 16 | 83 | -132 | 107 | 41 |
| 30 Sep 16 | 65 | -143 | 108 | 44 |
| 30 Jun 16 | 52 | -135 | 96 | 44 |
| 31 Mar 16 | 41 | -124 | 85 | 45 |
| 31 Dec 15 | 33 | -112 | 73 | 44 |
| 30 Sep 15 | 25 | -102 | 60 | 44 |
| 30 Jun 15 | 20 | -94 | 53 | 43 |
| 31 Mar 15 | 18 | -86 | 49 | 41 |
| 31 Dec 14 | 15 | -81 | 45 | 40 |
| 31 Dec 13 | 10 | -77 | 33 | 35 |
Quality Earnings: NVCR is currently unprofitable.
Growing Profit Margin: NVCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NVCR is unprofitable, and losses have increased over the past 5 years at a rate of 57.4% per year.
Accelerating Growth: Unable to compare NVCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVCR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).
Return on Equity
High ROE: NVCR has a negative Return on Equity (-41.52%), as it is currently unprofitable.